Board resignations reshape X4 Pharmaceuticals (NASDAQ: XFOR) audit panel

Rhea-AI Filing Summary

X4 Pharmaceuticals, Inc. reported that on August 22, 2025, directors David McGirr and R. Keith Woods resigned from its board of directors, including all board committees, effective immediately. The company stated that their resignations were not due to any disagreement regarding operations, policies, or practices.

Following these departures, Michael Wyzga was appointed chair of the board’s audit committee, and Francoise de Craecker and Gary Bridger were appointed as members of the audit committee, ensuring the committee remains staffed to oversee the company’s financial reporting and controls.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

0001501697FALSE00015016972025-08-222025-08-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 22, 2025

X4 PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-38295

27-3181608

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

61 North Beacon Street,			4th Floor
Boston,			Massachusetts						02134
(Address of principal executive offices)									(Zip Code)

(857) 529-8300

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

_______________________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

XFOR

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 22, 2025, David McGirr and R. Keith Woods resigned from the board of directors (the “Board”) of X4 Pharmaceuticals, Inc. (the “Company”), including all committees thereof, effective immediately. The resignations of Mr. McGirr and Mr. Woods from the Board are not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

In connection with the resignations of Messrs. McGirr and Woods, Michael Wyzga was appointed to serve as chair of the audit committee of the Board (the “Audit Committee”) and Francoise de Craecker and Gary Bridger were appointed to serve as members of the Audit Committee.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

X4 PHARMACEUTICALS, INC.

Date: August 25, 2025

By:

/s/ David H. Kirske

Name:

David H. Kirske

Title:

Chief Financial Officer

FAQ

What did X4 Pharmaceuticals (XFOR) disclose in this 8-K filing?

The company reported the resignations of two board members, David McGirr and R. Keith Woods, and the subsequent reconstitution of its audit committee with a new chair and two new members.

Which directors resigned from X4 Pharmaceuticals (XFOR) and when?

David McGirr and R. Keith Woods resigned from the board of directors, including all committees, effective August 22, 2025.

Were the X4 Pharmaceuticals board resignations due to a disagreement?

The company stated that the resignations of David McGirr and R. Keith Woods were not the result of any disagreement on matters relating to X4 Pharmaceuticals’ operations, policies, or practices.

Who is now chair of the X4 Pharmaceuticals audit committee?

Michael Wyzga has been appointed to serve as chair of the audit committee of the board of directors.

Who are the new members of X4 Pharmaceuticals’ audit committee?

Francoise de Craecker and Gary Bridger have been appointed to serve as members of the audit committee.

Does this filing mention any financial results for X4 Pharmaceuticals (XFOR)?

No, this filing focuses on changes to the board of directors and audit committee composition and does not provide financial results.